Janux Therapeutics JANX Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's change in AP?
- Janux Therapeutics (JANX) reported change in AP of -$1.61M in Q1 2026.
- How has Janux Therapeutics's change in AP changed year-over-year?
- Janux Therapeutics's change in AP increased by 1.5% year-over-year, from -$1.64M to -$1.61M.
- What is the long-term trend for Janux Therapeutics's change in AP?
- Over 2 years (2023 to 2025), Janux Therapeutics's change in AP has grown at a 87.8% compound annual growth rate (CAGR), from $277K to $977K.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.